Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ming-Lung Yu

Showing results (391-400 of 527) with videos related to

Pageof 53
Sort By:
Journal of Gastroenterology and Hepatology|July 24, 2025
Steatotic Liver Disease-Related Polygenetic Risk Score Prediction of Hepatocellular Carcinoma in Nucleotide/Nucleoside Analog-Treated Chronic Hepatitis BTyng-Yuan Jang, Chih-Wen Wang, Po-Cheng Liang, et al.
Hepatology International|May 28, 2016
APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testingMasao Omata, Tatsuo Kanda, Lai Wei, et al.
Journal of Gastroenterology and Hepatology|July 8, 2026
Chronic Viral Hepatitis With MASLD: Implications for Clinical and Patient-Reported OutcomesGeorge Papatheodoridis, Maria Buti, Yusuf Yilmaz, et al.
Oncotarget|February 5, 2017
Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearanceChung-Feng Huang, Ming-Lun Yeh, Ching-I Huang, et al.
Hepatology International|May 1, 2016
APASL consensus statements and recommendation on treatment of hepatitis CMasao Omata, Tatsuo Kanda, Lai Wei, et al.
Hepatology International|December 13, 2018
APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?Tatsuo Kanda, George K K Lau, Lai Wei, et al.
Oncotarget|August 20, 2016
Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapyMing-Ying Lu, Ching-I Huang, Ming-Yen Hsieh, et al.
Medicine|June 1, 2017
Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and databasePei-Chien Tsai, Ta-Wei Liu, Yi-Shan Tsai, et al.
World Journal of Gastroenterology|March 17, 2025
Mitochondrial mt12361A>G increased risk of metabolic dysfunction-associated steatotic liver disease among non-diabetesMing-Ying Lu, Yu-Ju Wei, Chih-Wen Wang, et al.
Journal of Viral Hepatitis|August 29, 2022
Severe impairment of patient-reported outcomes in patients with chronic hepatitis C virus infection seen in real-world practices across the world: Data from the global liver registryZobair M Younossi, Ming-Lung Yu, Mohamed El-Kassas, et al.
Pageof 53

Showing results (391-400 of 527) with videos related to

Sort By:
Pageof 53
Journal of Gastroenterology and Hepatology|July 24, 2025
Steatotic Liver Disease-Related Polygenetic Risk Score Prediction of Hepatocellular Carcinoma in Nucleotide/Nucleoside Analog-Treated Chronic Hepatitis BTyng-Yuan Jang, Chih-Wen Wang, Po-Cheng Liang, et al.
Hepatology International|May 28, 2016
APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testingMasao Omata, Tatsuo Kanda, Lai Wei, et al.
Journal of Gastroenterology and Hepatology|July 8, 2026
Chronic Viral Hepatitis With MASLD: Implications for Clinical and Patient-Reported OutcomesGeorge Papatheodoridis, Maria Buti, Yusuf Yilmaz, et al.
Oncotarget|February 5, 2017
Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearanceChung-Feng Huang, Ming-Lun Yeh, Ching-I Huang, et al.
Hepatology International|May 1, 2016
APASL consensus statements and recommendation on treatment of hepatitis CMasao Omata, Tatsuo Kanda, Lai Wei, et al.
Hepatology International|December 13, 2018
APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?Tatsuo Kanda, George K K Lau, Lai Wei, et al.
Oncotarget|August 20, 2016
Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapyMing-Ying Lu, Ching-I Huang, Ming-Yen Hsieh, et al.
Medicine|June 1, 2017
Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and databasePei-Chien Tsai, Ta-Wei Liu, Yi-Shan Tsai, et al.
World Journal of Gastroenterology|March 17, 2025
Mitochondrial mt12361A>G increased risk of metabolic dysfunction-associated steatotic liver disease among non-diabetesMing-Ying Lu, Yu-Ju Wei, Chih-Wen Wang, et al.
Journal of Viral Hepatitis|August 29, 2022
Severe impairment of patient-reported outcomes in patients with chronic hepatitis C virus infection seen in real-world practices across the world: Data from the global liver registryZobair M Younossi, Ming-Lung Yu, Mohamed El-Kassas, et al.
Pageof 53